New therapeutic target in primary headaches – blocking the CGRP receptor

Bibliography

• AMARA SG, JONAS V,ROSENFELD MG, ONG ES,EVANS RM: Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature (1982) 298:240–242.
   PubMed Web of Science ®Google Scholar
• SEXTON PM: Central nervous binding sites for calcitonin and calcitonin gene-related peptide. Mol Neurobiol (1991) 5:251–273.
   PubMed Web of Science ®Google Scholar
• BRAIN SD, CAMBRIDGE H: Calcitonin gene-related peptide: vasoactive effects and potential therapeutic role. Gen. Phannacol (1996) 27:607–611.
   Google Scholar
• UDDMAN R, EDVINSSON L, EKBLAD E, HAKANSON R, SUNDLER F: Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects. Regul Pept. (1986) 15:1–23.
   PubMedGoogle Scholar
• POYNER D, MARSHALL I, BRAIN SD: The CGRP family: calcitonin gene-related peptide (CGRP), amylin and adrenomedullin. Landes Bioscience, Georgetown, Texas, USA (2000):1–261.
   Google Scholar
• MCCULLOCH J, UDDMAN R, KINGMAN TA, EDVINSSON L: Calcitonin gene-related peptide. Functional role in cerebrovascular regulation. Proc. Natl. Acad. Li. USA (1986) 83:5731–5735.
   PubMed Web of Science ®Google Scholar
• ••First demonstration of thetrigemino-vascular reflex
   Google Scholar
• UDDMAN R, EDVINSSON L, EKMAN R, KINGMAN T, MCCULLOCH J: Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. NeuroscL Lett. (1985) 62:131–136.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, EDVINSSON L,EKMAN R: Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann. Neurol (1988) 23:193–196.
   PubMed Web of Science ®Google Scholar
• JANSEN-OLESEN I, MORTENSEN A,EDVINSSON L: Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia (1996) 16:310–316.
   PubMed Web of Science ®Google Scholar
• EDVINSSON L, JANSEN I,KINGMAN TA, MCCULLOCH J: Cerebrovascular responses to capsaicin in vitro and in situ. Br. J. Phannacol (1990) 100:312–318.
   Google Scholar
• EDVINSSON L: Aspects on the pathophysiology of migraine and cluster headache. Phannacol Toxicol (2001) 89:65–73.
   Google Scholar
• EDVINSSON L, EKMAN R, JANSEN I, OTTOSSON A, UDDMAN R: Peptide-containing nerve fibers in human cerebral arteries: immunohistochemistry, radioimmunoassay and in vitro pharmacology. Ann. Neurol (1987) 21:431–437.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ: Inhibition of calcitonin gene-related peptide by h-CGRP8_37 antagonizes the cerebral dilator response from nasociliary nerve stimulation in the cat. Neurosci. Lett. (1993) 151:13–16.
   PubMedGoogle Scholar
• GULBENKIAN S, UDDMAN R, EDVINSSON L: Neuronal messengers in the human cerebral circulation. Peptides (2001) 22:995–1007.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, EDVINSSON L, EKMAN R: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol (1990) 28:183–187.
   PubMed Web of Science ®Google Scholar
• ••First demonstration of the selective releaseof CGRP in conjunction with migraine attacks in man. It was also pointed out that substance P was not released from the sensory nerves, nor transmitters from the autonomic nerves.
   Google Scholar
• EDVINSSON L, HARA H, UDDMAN R: Retrograde tracing of nerve fibers to the rat middle cerebral artery with true blue: localization with different peptides. Cereb. Blood Flow Metab. (1989) 9:212–218.
   PubMedGoogle Scholar
• TAJTI J, UDDMAN,R, MOLLER S, SUNDLER F, EDVINSSON L:Messenger molecules and receptor mRNA in the human trigeminal ganglion. J. Auton. Nerv. Syst. (1999) 76:176–183.
   PubMedGoogle Scholar
• GALLAI V, SARCHIELLE P, FLORIDI A et al: Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia (1995) 15:384–390.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, EDVINSSON L:The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. NeuroL (1993) 33:48–56.
   PubMed Web of Science ®Google Scholar
• ••Demonstration in man and cat that thetriptan sumatriptan and dihydroergotamine could act not only directly on cerebral blood flow to reduce the response to trigeminal activation but also to inhibit CGRP release via prejunctional inhibition.
   Google Scholar
• HOU M, KANJE M, LONGMORE J, TAJTI J, UDDMAN R, EDVINSSON L: 5-HT1B and 5-HT1p receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res. (2001) 909:112–120.
   PubMed Web of Science ®Google Scholar
• SMITH D, HILL RG, EDVINSSON L, LONGMORE J: An immunocytochemical investigation of human trigeminal nucleus caudalis: CGRP, substance P and 5-HT1D receptor immunoreactivities are expressed by trigeminal sensory fibres. Cephalalgia (2002) 22:424–431.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, EDVINSSON L: Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain (1994) 117:427–434.
   Google Scholar
• ••First demonstration of CGRP release incluster headache. In addition, the release of VIP from parasympathetic nerves suggests an additional mechanism to the illustrated facial symptoms.
   Google Scholar
• FANCIULLACCI M, ALESSANDRI M, FIGINI M, GEPPETTI P,MICHELACCI S: Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain (1995) 60:119–123.
   PubMed Web of Science ®Google Scholar
• FANCIULLACCI M, ALESSANDRI M, SICUTERI R, MARABINI S: Responsiveness of the trigeminovascular system to nitroglycerine in cluster headache patients. Brain (1997) 120:283–288.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, EDVINSSON L,EKMAN R: Cutaneous sensory stimulation leading to facial flushing and release of calcitonin gene-related peptide. Cephalalgia (1992) 12:53–56.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, EDVINSSON L: Neuropeptide changes in a case of chronic paroxysmal hemicrania: evidence for trigemino-parasympathetic activation. Cephalalgia (1996) 16:448–450.
   PubMed Web of Science ®Google Scholar
• WAUGH DJ, BOCKMAN J, SMITH C, ABEL PW: Limitations in using peptide drugs to characterize calcitonin gene-related peptide receptors. I Pharmacol Exp. Ther. (1999) 289:1419–1426.
   PubMedGoogle Scholar
• AIYAR N, RAND K,ELSHOURBAGY NA et al.: A cDNA encoding the calcitonin gene-related peptide Type I receptor. J. Biol. Chem. (1996) 271:11325–11329.
   Google Scholar
• MCLATCHIE LM, FRASER NJ, MAIN MJ et al: RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature (1998) 393:333–339.
   PubMed Web of Science ®Google Scholar
• ••Demonstration of the importance of thesubelements of the CGRP receptor, the RAMPs.
   Google Scholar
• FOORD SM, MARSHALL FH: RAMPs: accessory proteins for seven transmembrane domain receptors. Trends Pharmacol Li. (1999) 20:184–187.
   PubMed Web of Science ®Google Scholar
• KUWASAKO K, SHIMEKAKE Y, MASUDA M et al.: Visualization of the calcitonin receptor-like receptor and its receptor activity-modifying proteins during internalization and recycling. J. Biol. Chem. (2000) 275:29602–29609.
   PubMed Web of Science ®Google Scholar
• ARMOUR SL, FOORD S, KENAKIN T, CHEN WJ: Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor. J. Pharmacol Toxicol Methods (1999) 42:217–224.
   PubMed Web of Science ®Google Scholar
• CHRISTOPOLOUS G, PERRY KJ, MORFIS M et al: Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol. Pharmacol (1999) 56:235–242.
   PubMedGoogle Scholar
• LUEBKE AE, DAHL GP, ROOS BA, DICKERSON IM: Identification of a protein that confers calcitonin gene-related peptide responsiveness to oocytes by using a cystic fibrosis transmembrane conductance regulator assay. Proc. Natl. Acad. Li. USA (1996) 93:3455–3460.
   PubMed Web of Science ®Google Scholar
• EVANS BN, ROSENBLATT MI, MAYER LO, OLIVER KR,DICKERSON IM: CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. J. Biol. Chem. (2000) 275:31438–31443.
   PubMed Web of Science ®Google Scholar
• EDVINSSON L, GOADSBY PJ, UDDMAN R: Amylin: localization, effects on cerebral arteries and on local cerebral blood flow in the cat. The Scientific World (2001) 1:168–180.
   Google Scholar
• JANSEN-OLESEN I, KAARILL L, EDVINSSON L: Characterization of CGRP(1) receptors in the guinea pig basilar artery. Eur. PharmacoL (2001) 414:249–258.
   PubMed Web of Science ®Google Scholar
• EDVINSSON L, CANTERA L, JANSEN-OLESEN I, UDDMAN R: Expression of calcitonin gene-related peptide 1 receptor mRNA in human trigeminal ganglia and cerebral arteries. Neurosci. Lett. (1997) 229:209–211.
   PubMedGoogle Scholar
• SAMS A, JANSEN-OLESEN I: Expressionof calcitonin receptor-like receptor (CRLR) and receptor-activity-modifying proteins in human cranial arteries. Neurosci. Lett. (1998) 258:41–44.
   PubMed Web of Science ®Google Scholar
• OLIVER KR, WAINWRIGHT A, EDVINSSON L, PICKARD JG, HILL RG: Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature. ./. Cereb. Blood Flow Metab. (2002) 22:620–629.
   PubMed Web of Science ®Google Scholar
• ••Elegant demonstration of the varioussubelements of the CGRP receptor on thehuman intracranial vessels, putatively the main target of released CGRP and of a future drug.
   Google Scholar
• DOODS H, HALLERMAYER G, WU D et al.: Pharmacological profile of BIBN-4096B5, the first selective small molecule CGRP antagonist. BE J. PharmacoL (2000) 129:420–423.
   PubMed Web of Science ®Google Scholar
• ••Illustration of the basic pharmacology ofthe first CGRP receptor antagonist that has gone into clinical testing.
   Google Scholar
• EDVINSSON L, SAMS A, JANSEN-OLESEN I et al: Characterization of the effects of a non-peptide CGRP receptor antagonist in SK-N-MC cells and isolated human cerebral arteries. Eur. Pharmacol (2001) 415:39–44.
   PubMed Web of Science ®Google Scholar
• MALLEE J, SALVATORE CA, LEBOURDELLES B et al.: Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. Biol Chem. (2002) 277:14294–14298.
   Google Scholar
• POWELL KJ, MAW, SUTAK M, DOODS H, QUIRION R,JHAMANDAS K: Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists. Br. Pharmacol (2000) 131:875–884.
   PubMedGoogle Scholar
• EDVINSSON L, ALM R, SHAW D et al: Effect of the CGRP receptor antagonist BIBN-4096B5 in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur. Pharmacol (2002) 434:49–53.
   PubMed Web of Science ®Google Scholar
• AIYAR N, DAINES RA, DISA J et al: Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonist. J. Pharmacol Exp. Ther. (2001) 296:768–775.
   PubMed Web of Science ®Google Scholar